TrialJournal for immunotherapy of cancer2024

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.

David P Carbone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.